Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis

Digestive Diseases and Sciences

Volumn 53, Issue 7, 2008, Pages 1988-1993

  Stanca, Carmen M ^a   Bach, Nancy ^a   Allina, Jorge ^a   Bodian, Carol ^a   Bodenheimer Jr , Henry ^b   Odin, Joseph A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Biliary; Cholesterol; Hydroxymethylglutaryl coA reductase inhibitors; Hyperlipidemias; Immunosuppression; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ATORVASTATIN; BILIRUBIN; LOW DENSITY LIPOPROTEIN;

AGE DISTRIBUTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILIARY CIRRHOSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MALE; MYALGIA; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; TREATMENT RESPONSE;

AGED; ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRROLES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 44449143344     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0003-2     Document Type: Article

References (36)

1. Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353:1261-1273
2. Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, Klintmalm GB, Wiesner RH, Van Thiel DH, Starzl TE (1989) Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 320:1709-1713
3. Del Puppo M, Kienle MG, Petroni ML, Crosignani A, Podda M (1998) Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res 39:2477-2482
4. Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB Jr (1985) Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89:1266-1278
5. Aly A, Carlson K, Johansson C, Kirstein P, Rossner S, Wallentin L (1984) Lipoprotein abnormalities in patients with early primary biliary cirrhosis. Eur J Clin Invest 14:155-162
6. Propst A, Propst T, Lechleitner M, Hoppichler F, Kathrein H, Vogel W, Judmaier G, Knapp E, Braunsteiner H (1993) Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci 38:379-380
7. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER (1992) Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? Hepatology 15:858-862
8. Leonhardt U, Nather M, Ramadori G (1997) Primary biliary cirrhosis. N Engl J Med 336:1387, discussion 1388
9. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M (2002) Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51:265-269
10. Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM (2006) Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55:1795-1800
11. Sorokin A, Brown JL, Thompson PD (2007) Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 194:293-299
12. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89:1084-1091
13. Lombard M, Portmann B, Neuberger J, Williams R, Tygstrup N, Ranek L, Ring-Larsen H, Rodes J, Navasa M, Trepo C et al (1993) Cyclosporin a treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104:519-526
14. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15:336-344
15. Bach N, Thung SN, Schaffner F (1998) The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 122:342-345
16. Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D (1999) Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117:400-407
17. Heathcote EJ (2000) Management of primary biliary cirrhosis. The American association for the study of liver diseases practice guidelines. Hepatology 31:1005-1013
18. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627
19. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402
20. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207-213
21. Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y et al (1993) Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 15:890-898
22. Kamisako T, Adachi Y (1995) Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 90:1187-1188
23. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G (2002) Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 36:454-458
24. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (ppp) project. Circulation 105:2341-2346
25. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47:135-141
26. Parra JL, Reddy KR (2003) Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7:415-433
27. Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, Gips CH (1994) Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 20:126-134
28. Kim WR, Lindor KD, Malinchoc M, Petz JL, Jorgensen R, Dickson ER (2000) Reliability and validity of the niddk-qa instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology 32:924-929
29. Prince MI, James OF, Holland NP, Jones DE (2000) Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 32:368-373
30. Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, James OF, Jones DE (2002) The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 122:1235-1241
31. Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, Bodian C, Lopez J, Berk PD, Bodenheimer HC Jr, Branch AD, Odin JA (2005) Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 100:1104-1109
32. Evans M, Rees A (2002) Effects of hmg-coa reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25:649-663
33. Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL (2006) Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55:536-541
34. Clarke AT, Mills PR (2006) Atorvastatin associated liver disease. Dig Liver Dis 38:772-777
35. Khorashadi S, Hasson NK, Cheung RC (2006) Incidence of statin hepatotoxicity in patients with hepatitis c. Clin Gastroenterol Hepatol 4:902-907, quiz 806
36. Gibson K, Rindone JP (2005) Experience with statin use in patients with chronic hepatitis c infection. Am J Cardiol 96:1278-1279